Physician profile
Bryan E Lee
NPI 1790020618
$1,181.50
in general payments reported to CMS, 2019-2025
18 companies · $18.90 in 2025
The $18.90 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $97.09 · 2021: $153 · 2022: $101 · 2025: $18.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $265.31 | 2019-2021 | |
| Incyte Corporation | $125.00 | 2019 | |
| Seagen INC. | $123.24 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $118.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $114.66 | 2019-2020 | |
| Clovis Oncology, INC. | $99.95 | 2019 | |
| Lilly USA, LLC | $81.43 | 2019-2021 | |
| Eisai INC. | $65.47 | 2019 | |
| Genentech USA, INC. | $28.78 | 2019-2022 | |
| Daiichi Sankyo INC. | $27.67 | 2022 | |
| Myriad Genetic Laboratories, INC. | $20.78 | 2022 | |
| Beigene USA, INC. | $20.40 | 2022 | |
| Abbvie INC. | $18.90 | 2025 | |
| Pfizer INC. | $16.29 | 2020 | |
| Fortovia Therapeutics, INC. | $14.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.19 | 2022 | |
| Rigel Pharmaceuticals, INC. | $13.76 | 2019 | |
| Janssen Biotech, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.